|Videos|April 1, 2021
Role of Bevacizumab for Initial Therapy in Advanced Ovarian Cancer
Author(s)Rebecca Previs, MD
An expert in gynecologic oncology talks about the role of bevacizumab in the front-line management of advanced ovarian cancer.
Advertisement
Advertisement
Related to this article
New analyses from the RAMP 201 trial demonstrated responses in KRAS wild-type recurrent LGSOC with avutometinib plus defactinib.
Data from RAINFOL-01 showed rinatabart sesutecan achieved responses in heavily pretreated platinum-resistant ovarian cancer with low or no FRα expression.
Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Reading a Changed Eye Examination and Impact on Therapy
2
Operationalizing the First Dose and Building the Oncology and Eye Care Partnership
3
FDA Expands Approval for Nogapendekin Alfa in BCG-Unresponsive NMIBC
4
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
5